TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
$LLY · GLP-1s, Peptides, and The Trillion-Dollar Health Revolution
now playing · $LLY
$LLY···bullish· high· posalex cornell
Eli Lilly's GLP-1 franchise proves trillion-dollar preventive health thesis with oral Wegovy accelerating adoption 4x
Oral Wegovy at $150/month is driving record adoption (300k new scripts/week vs 200k), proving massive price elasticity and consumer demand for preventive metabolic medicine; Lilly…
$NVO···bullish· high· posalex cornell
Novo Nordisk's GLP-1 cardiovascular outcome data shows 20%+ risk reduction independent of weight loss
SELECT trial data demonstrates cardioprotective benefit beyond weight loss, confirming GLP-1s as foundational preventive medicine; compounded GLP-1 price elasticity (15-20% market…
$EXAS···bullish· medium· posalex cornell
Exact Sciences' Cologuard stool test proves commercial viability of non-invasive colorectal screening
Stool-based test with incredible predictive ability for colorectal cancer risk has established a growing market, validating the category for liquid biopsy approaches; colonoscopy…
$GH···bullish· medium· posalex cornell
Guardant Health's blood-based Shield test inflecting as next-gen colorectal screening with superior commercial model
Blood test eliminates stool collection friction, enabling scale that stool tests cannot achieve; commercial inflection visible in recent data as physicians and patients adopt simp…
$CAPSTANbullish· medium· posalex cornell
Capstan's in vivo CAR-T achieves 100% tumor reduction in 70%+ patients without cell extraction
Next-gen IV-delivered CAR-T eliminates need for patient cell harvesting and manufacturing, enabling off-the-shelf cell therapy with dramatic efficacy in hematologic malignancies;…
$LILA-SCIENCESbullish· high· posalex cornell
Lila Sciences demonstrates AI-driven model-to-molecule in one month with automated robotic labs
Agentic AI systems combined with robotic automation are already compressing hit-to-lead timelines from years to months; closed-loop 'science factories' generate proprietary data t…
$ENABLAbullish· medium· posalex cornell
Enabla's AI platform achieves model-to-molecule in weeks, validating in silico screening at scale
Alongside Lila Sciences, Enabla proves AI can systematically screen and design molecules against known targets in silico, replacing massive physical screens; early commercial vali…
$BIIB···neutral· lowalex cornell
Biogen's anti-amyloid Leqembi shows 30% cognitive decline slowing in late-stage Alzheimer's
Anti-amyloid antibodies (Leqembi with Eisai, donanemab with Lilly) demonstrate plaque clearance and modest clinical benefit in symptomatic patients; real opportunity lies in earli…